Biography

Dr. Chackerian grew up in Northern California, received his BA at the University of California, Berkeley in 1990 and his PhD studying the immune selection of Simian Immunodeficiency Virus with Julie Overbaugh at the University of Washington in 1996. He then trained in John Schiller's laboratory at the National Cancer Institute. In 2004 he joined the Department of Molecular Genetics and Microbiology at the University of New Mexico School of Medicine.

Personal Statement

The Chackerian laboratory is interested in vaccine development; particularly the use of virus particles as platforms for antigen display. It has long been recognized that highly dense repetitive antigens such as virus particles induce strong immune responses. Our lab has demonstrated that antigens that are normally poorly immunogenic can be made highly immunogenic by displaying them in a multivalent, repetitive format on the surface of virus particles; essentially using viruses as scaffolds to produce novel vaccines.

This ability to enhance immunogenicity does not only apply to epitopes derived from traditional targets, such as pathogens, but also to self-antigens which are normally subject to the mechanisms of B cell tolerance. Using virus-like particles derived from RNA bacteriophage, the Chackerian lab has collaborated with David Peabody to develop a variety of tools for vaccine production and to implement a system that allows vaccines to be rapidly identified by affinity selection.

The laboratory has projects to develop novel vaccines targeting Human Papillomavirus (HPV), Neisseria gonorrhoeae (in collaboration with Ann Jerse and the Gonorrhea Vaccine Cooperative Research Center), Chlamydia (in collaboration with Kathryn Frietze), Malaria (in collaboration with Fidel Zavala and Nik Petrovsky), HIV (in collaboration with Daniel Lingwood and Moriya Tsuji), Influenza (in collaboration with Daniel Lingwood), Zika virus, Staphylococcus (in collaboration with Pam Hall), Alzheimer's Disease (in collaboration with Kiran Bhaskar), and high cholesterol (in collaboration with Alan Remaley).

To learn more about our work, follow us on Twitter (@chacklab) or, to see a complete list of publications, go to:
https://pubmed.ncbi.nlm.nih.gov/?term=chackerian+b&sort=date


Achievements & Awards

Jeffrey Michael Gorvetzian Endowed Professor of Biomedical Research Excellence
STC.UNM (Science and Technology Center at UNM) Innovation Fellow, 2017
Biomedical Sciences Graduate Program Outstanding Mentor Award, 2019
Fellow of the National Academy of Inventors, 2019

Research

The Chackerian laboratory is interested in vaccine development; particularly the use of virus particles as platforms for antigen display. It has long been recognized that highly dense repetitive antigens such as virus particles induce strong immune responses. Our lab has demonstrated that antigens that are normally poorly immunogenic can be made highly immunogenic by displaying them in a multivalent, repetitive format on the surface of virus particles; essentially using viruses as scaffolds to produce novel vaccines.

This ability to enhance immunogenicity does not only apply to epitopes derived from traditional targets, such as pathogens, but also to self-antigens which are normally subject to the mechanisms of B cell tolerance. Using virus-like particles derived from RNA bacteriophage, the Chackerian lab has collaborated with David Peabody to develop a variety of tools for vaccine production and to implement a system that allows vaccines to be rapidly identified by affinity selection.

The laboratory has projects to develop novel vaccines targeting Human Papillomavirus (HPV), Neisseria gonorrhoeae (in collaboration with Ann Jerse and the Gonorrhea Vaccine Cooperative Research Center), Chlamydia (in collaboration with Kathryn Frietze), Malaria (in collaboration with Fidel Zavala and Nik Petrovsky), HIV (in collaboration with Daniel Lingwood and Moriya Tsuji), Influenza (in collaboration with Daniel Lingwood), Zika virus, Staphylococcus (in collaboration with Pam Hall), Alzheimer's Disease (in collaboration with Kiran Bhaskar), and high cholesterol (in collaboration with Alan Remaley). To learn more about our work, follow us on Twitter.

Group photo.
Chackerian Lab (October 2019)

Lab Members:

  • Julianne Peabody (PhD student)
  • Dr. Lucie Jelinkova (Post-doctoral fellow)
  • Dr. Alex Francian (Post-doctoral fellow)
  • Rabia Khan (MS student)
  • Javier Leo (Research Technician)
  • Bryce Roberts (Research Scientist)

Lab Alumni:

  • Dr. Zoe Hunter (PhD student), Senior Manager, Publications at Pharmacyclics, an AbbVie company
  • Marisa Rangel Durfee (Research Technician), Grants Program Manager at Circumvent Pharamaceuticals
  • Dr. Brett Manifold-Wheeler (Research Technician), Post-doctoral fellow, UNM Cancer Center
  • Dr. Paul Durfee (Research Technician), Senior Scientist at Janssen Inc.
  • Alex Medford (MS student), Scientist, Colorado Department of Health
  • Dr. John O'Rourke (Research Assistant Professor), Director of Assay Development, BennuBio Inc.
  • Dr. Jayne Christen (Post-doctoral fellow), Scientific Project Manager, Leidos/NCI Frederick
  • Dr. Mitchell Tyler (PhD student), Senior Analyst, National Center for Medical Intelligence
  • Dr. Erin Crossey (MD/PhD student), Pulmonary Fellowship Program, Boston University
  • Dr. Ebenezer Tumban (Post-doctoral fellow/Research scientist), Associate Professor, Texas Tech University (Amarillo)
  • Dr. Kathryn Frietze (Post-doctoral fellow/Research Assistant Professor), Assistant Professor, UNM School of Medicine
  • Susan Core (Sr Research Specialist), Research Specialist, Frietze Laboratory, UNM
  • Dr. Naomi Lee (Post-doctoral fellow), Assistant Professor, Northern Arizona University
  • Dr. Alemu Mogus (Post-doctoral fellow), Post-doctoral fellow, University of Virginia
  • Dr. Alexandra Fowler (PhD student), Post-doctoral fellow at Merck
  • Ashvini Vaidya (MS student and research scientist), Medical student at Emory University
  • Temi Ajayi (Research Technician), Medical student at UNM School of Medicine

Research and Scholarship

Representative publications include:<br><br>Fowler, A., Sampson, M., Remaley, A.T., and <b>B. Chackerian</b><b>(2021)</b>. A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice. <b>Vaccine</b>, 2021 Sep 24;39(40):5780-5786.<br><br>Ronsard, L., Yousif, A., Peabody, J., Okonkowo, V., Devant, P., Mogus, A.T., Barnes, R., Rohrer, D., Lonberg, N., Peabody, D., <b>Chackerian, B.,</b> and D. Lingwood <b>(2021)</b>. Engineering an antibody V gene-selective vaccine. <b>Frontiers in Immunology</b>, 2021 Sep 9;12:730471<br><br>Lucie Jelínková, Hugo Jhun, Allison Eaton, Nikolai Petrovsky, Fidel Zavala, & <b>Bryce Chackerian (2021)</b>. An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein. <b>npj Vaccines</b> 2021 Jan 21;6(1):13.<br><br>Mogus, A.T.; Liu, L.; Jia, M.; Ajayi, D.T.; Xu, K.; Kong, R.; Huang, J.; Yu, J.; Kwong, P.D.; Mascola, J.R.; Ho, D.D.; Tsuji, M.; <b>Chackerian, B. (2020)</b> Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. <b>Vaccines</b>, <i>8</i>, 765.<br><br>Bryce Chackerian and David S. Peabody (2020). Factors that Govern the induction of long-lived Plasma Cells. <b>Viruses</b>. 12, 74;